ALX ONCOLOGY HOLDINGS INC Costs and Expenses, Related Party
ALX ONCOLOGY HOLDINGS INC (ALXO) reported Costs and Expenses, Related Party of $1.07 million for the 12-month period ending 2020-12-31, per its 10-K filed 2023-03-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:CostsAndExpensesRelatedParty · last filed 2023-03-09
- ALX ONCOLOGY HOLDINGS INC costs and expenses, related party for the quarter ending 2020-12-31 was $0.00, a 100.00% decline year-over-year.
- ALX ONCOLOGY HOLDINGS INC costs and expenses, related party for the quarter ending 2020-09-30 was $0.00, a 100.00% decline year-over-year.
- ALX ONCOLOGY HOLDINGS INC costs and expenses, related party for the quarter ending 2020-06-30 was $479.00K, a 59.30% decline year-over-year.
- ALX ONCOLOGY HOLDINGS INC costs and expenses, related party for the quarter ending 2020-03-31 was $596.00K.
- ALX ONCOLOGY HOLDINGS INC costs and expenses, related party for fiscal 2020 was $1.07M, a 75.34% decline from fiscal 2019.
- ALX ONCOLOGY HOLDINGS INC costs and expenses, related party for fiscal 2019 was $4.36M, a 131.91% increase from fiscal 2018.
- ALX ONCOLOGY HOLDINGS INC costs and expenses, related party for fiscal 2018 was $1.88M.
| Period end | Costs and Expenses, Related Party 3 month | Costs and Expenses, Related Party 6 month | Costs and Expenses, Related Party 9 month | Costs and Expenses, Related Party 12 month |
|---|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $0.00 derived: sum of 2 quarters · filed 2023-03-09 | $479.00K derived: sum of 3 quarters · filed 2023-03-09 | $1.07M 10-K · filed 2023-03-09 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $479.00K derived: sum of 2 quarters · filed 2021-11-12 | $1.07M 10-Q · filed 2021-11-12 | $2.18M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $479.00K 10-Q · filed 2021-08-12 | $1.07M 10-Q · filed 2021-08-12 | $2.18M derived: sum of 3 quarters · filed 2022-02-28 | $3.32M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $596.00K 10-Q · filed 2021-05-17 | $1.70M derived: sum of 2 quarters · filed 2022-02-28 | $2.84M derived: sum of 3 quarters · filed 2022-02-28 | $4.02M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $2.25M derived: sum of 2 quarters · filed 2022-02-28 | $3.42M derived: sum of 3 quarters · filed 2022-02-28 | $4.36M 10-K · filed 2022-02-28 |
| 2019-09-30 | $1.14M 10-Q · filed 2020-11-12 | $2.32M derived: sum of 2 quarters · filed 2020-11-12 | $3.26M 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $1.18M 10-Q · filed 2020-08-27 | $2.12M 10-Q · filed 2020-08-27 | ||
| 2018-12-31 | $1.88M 10-K · filed 2021-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |